These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 27556299)
1. Body mass index as a prognostic factor in patients with extranodal natural killer/T-cell lymphoma, nasal type. Liu J; Deng YT; Zhang L; Li N; Jiang M; Zou LQ; Jiang Y Oncotarget; 2016 Nov; 7(47):78159-78167. PubMed ID: 27556299 [TBL] [Abstract][Full Text] [Related]
2. Increased body mass index is associated with improved overall survival in extranodal natural killer/T-cell lymphoma, nasal type. Li YJ; Yi PY; Li JW; Liu XL; Liu XY; Zhou F; OuYang Z; Sun ZY; Huang LJ; He JQ; Yao Y; Fan Z; Tang T; Jiang WQ Oncotarget; 2017 Jan; 8(3):4245-4256. PubMed ID: 28002803 [TBL] [Abstract][Full Text] [Related]
3. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma. Niu SQ; Yang Y; Li YY; Wen G; Wang L; Li ZM; Wang HY; Zhang LL; Xia YF; Zhang YJ Chin J Cancer; 2016 Apr; 35():34. PubMed ID: 27044275 [TBL] [Abstract][Full Text] [Related]
4. CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Li P; Jiang L; Zhang X; Liu J; Wang H BMC Cancer; 2014 Nov; 14():890. PubMed ID: 25429803 [TBL] [Abstract][Full Text] [Related]
5. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type. Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540 [TBL] [Abstract][Full Text] [Related]
6. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis. Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537 [TBL] [Abstract][Full Text] [Related]
7. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy. Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116 [TBL] [Abstract][Full Text] [Related]
8. The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type. Chen KL; Liu YH; Li WY; Chen J; Gu YK; Geng QR; Jiang WQ; Huang HQ; Lin TY; Xia ZJ; Cai QQ Ann Hematol; 2015 Aug; 94(8):1389-400. PubMed ID: 25869028 [TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma. Yoo C; Yoon DH; Jo JC; Yoon S; Kim S; Lee BJ; Huh J; Lee SW; Suh C Ann Hematol; 2014 Jun; 93(6):995-1000. PubMed ID: 24441948 [TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma. Yang CW; Wang CW; Hong RL; Tsai CL; Yao M; Tang JL; Lin CW; Cheng AL; Kuo SH J Radiat Res; 2017 Jan; 58(1):114-122. PubMed ID: 27534792 [TBL] [Abstract][Full Text] [Related]
11. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study. Zhang Y; Ma S; Cai J; Yang Y; Jing H; Shuang Y; Peng Z; Li B; Liu P; Xia Z; Xia Y; Gao Y; Chen D; Lin J; Li Q; Xu S; Xu Q; Zhang H; Huang H; Cai Q Am J Hematol; 2021 Nov; 96(11):1481-1490. PubMed ID: 34449095 [TBL] [Abstract][Full Text] [Related]
12. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS; Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611 [TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of absolute lymphocyte count/absolute monocyte count ratio and prognostic score in patients with nasal-type, extranodal natural killer/T-cell lymphoma. Li N; Zhang L; Song HL; Zhang J; Weng HW; Zou LQ Tumour Biol; 2017 May; 39(5):1010428317705503. PubMed ID: 28475009 [TBL] [Abstract][Full Text] [Related]
14. The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage. Zeng L; Huang W; Cao Z; Zheng B; Liu X; Guo L; Feng X Ann Hematol; 2019 Jun; 98(6):1467-1476. PubMed ID: 30895352 [TBL] [Abstract][Full Text] [Related]
15. Development of new prognostic model based on pretreatment βLRI and LLRI for stage IE/IIE upper aerodigestive tract ENKTL, nasal type. Dai W; Jia B; Yang J; Zhou S; Liu P; He X; Qin Y; Gui L; Zhang C; Han X; Sun Y; Shi Y Oncotarget; 2017 May; 8(21):34787-34795. PubMed ID: 28410236 [TBL] [Abstract][Full Text] [Related]
16. Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer/T-cell lymphoma, nasal type: a retrospective controlled study in a single center. Wang J; Wei L; Ye J; Yang L; Li X; Cong J; Yao N; Cui X; Wu Y; Ding J; Zhang L Int J Hematol; 2018 Jan; 107(1):98-104. PubMed ID: 28856590 [TBL] [Abstract][Full Text] [Related]
17. A proposal for a prognostic index for non-nasal type natural killer/T cell lymphoma after asparaginase-based treatment. Chen Z; Fang X; Huang H; Wang Z; Hong H; Chen M; Ren Q; Yao Y; Zhang L; Tian Y; Lin S; Lin T Ann Hematol; 2020 Dec; 99(12):2811-2819. PubMed ID: 32975588 [TBL] [Abstract][Full Text] [Related]
18. Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma. Huang Y; Jia B; Jiang S; Zhou S; Yang J; Liu P; Gui L; He X; Qin Y; Sun Y; Shi Y J Hematol Oncol; 2017 Jan; 10(1):7. PubMed ID: 28057019 [TBL] [Abstract][Full Text] [Related]
19. [Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma]. Wu T; Liu QL; Hu YF; Zhang J; Chen MX; Chen XX; Huang YH; Lu B Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):859-864. PubMed ID: 31770855 [No Abstract] [Full Text] [Related]
20. CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type. Wang L; Wang H; Li PF; Lu Y; Xia ZJ; Huang HQ; Zhang YJ Ann Hematol; 2015 Aug; 94(8):1381-8. PubMed ID: 25865943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]